Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Stock Information for Purple Biotech Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Purple Biotech Ltd.

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.